Karen L Houseknecht

Dr. Karen L Houseknecht

University of New England, Maine USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
PHPai-Kai Huang
Pai-Kai Huang
SAShawn M. Aarde
Shawn M. Aarde
DADeepshikha Angrish
Deepshikha Angrish
TDTobin J. Dickerson
Tobin J. Dickerson
MTMichael A. Taffe
Michael A. Taffe
Karen L HouseknechtKaren L Houseknecht
Karen L Houseknecht

15 November 2022 in Frontiers in Neuroscience
Verified
Journal Article
Open access
AGAnwesha Gangopadhyay
Anwesha Gangopadhyay
RIRadwa Ibrahim
Radwa Ibrahim
KTKarli Theberge
Karli Theberge
MMMeghan May
Meghan May
Karen L HouseknechtKaren L Houseknecht
Karen L Houseknecht
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and one of the leading indications for liver transplantation. It is one of the many manifestations of insulin resistance and metabolic syndrome as well as an independent risk factor for cardiovascular disease. There is growing evidence linking the incidence of NAFLD with psychiatric illnesses such as schizophrenia, bipolar disorder and depression mechanistically via genetic, metabolic, inflammatory and environmental factors including smoking and psychiatric medications. Indeed, patients prescribed antipsychotic medications, regardless of diagnosis, have higher incidence of NAFLD than population norms. The mechanistic pharmacology of antipsychotic-associated NAFLD is beginning to emerge. In this review, we aim to discuss the pathophysiology of NAFLD including its risk factors, insulin resistance and systemic inflammation as well as its intersection with psychiatric illnesses.

26 June 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMeghan May
Meghan May
MBMegan Beauchemin
Megan Beauchemin
CVCalvin Vary
Calvin Vary
DBDeborah Barlow
Deborah Barlow
Karen L HouseknechtKaren L Houseknecht
Karen L Houseknecht
Atypical antipsychotic medications such as risperidone are widely prescribed for diverse psychiatric indications including schizophrenia, bipolar disorder and depression. These medications have complex pharmacology and are associated with significant endocrine and metabolic side effects. This class of medications also carries FDA black box warnings due to increased risk of death in elderly patients. Clinical reports indicate that patients treated with these medications are more susceptible to infections; however, the underlying mechanisms/pharmacology are unclear. We have previously reported that risperidone and it’s active metabolite distributes to the bone marrow in clinically relevant concentrations in preclinical species, leading us to hypothesize that the hematopoietic system may be impacted by these medications. To test this hypothesis, using proteomic and cytokine array technology, we evaluated the expression of genes involved in inflammatory and immune function following short term (5 days) and longer term (4 weeks) treatment in healthy animals. We report that low-dose risperidone treatment results in global immunosuppression in mice, observed following 5 days of dosing and exacerbated with longer term drug treatment (4 weeks). These data are consistent with increased susceptibility to infection in patients administered these medications and have profound implications for the increasing off-label prescribing to vulnerable patient populations including children and the elderly.

15 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DCDejan Caglič
Dejan Caglič
MKMichelle C. Krutein
Michelle C. Krutein
KBKristin M. Bompiani
Kristin M. Bompiani
DBDeborah J. Barlow
Deborah J. Barlow
GBGalit Benoni
Galit Benoni
Karen L HouseknechtKaren L Houseknecht
Karen L Houseknecht

1 October 2017 in Bone
Verified
Journal Article
Closed access
KMKatherine J. Motyl
Katherine J. Motyl
MBMegan Beauchemin
Megan Beauchemin
DBDeborah Barlow
Deborah Barlow
PLPhuong T. Le
Phuong T. Le
KNKenichi Nagano
Kenichi Nagano
Karen L HouseknechtKaren L Houseknecht
Karen L Houseknecht

1 July 2020 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
MMMeghan May
Meghan May
MSMatthew Slitzky
Matthew Slitzky
Bahman RostamaBahman Rostama
Bahman Rostama
DBDeborah Barlow
Deborah Barlow
Karen L HouseknechtKaren L Houseknecht
Karen L Houseknecht
Patients with severe mental illness are more susceptible to infections for a variety of reasons, some associated with the underlying disease and some due to environmental factors including housing insecurity, smoking, poor access to healthcare, and medications used to treat these disorders. This increased susceptibility to respiratory infections may contribute to risk of COVID-19 infection in patients with severe mental illness or those in inpatient settings. Atypical antipsychotic (AA) medications are FDA approved to treat symptoms associated with schizophrenia, bipolar disorder, depression and irritability associated with autism. Our team and others have shown that AA may have anti-inflammatory properties that may contribute to their efficacy in the treatment of mental health disorders. Additionally, AA are widely prescribed off-label for diverse indications to non-psychotic patients including older adults, who are also at increased risk for COVID-19 complications and mortality. The aim of this study was to determine if AA medications such as risperidone (RIS) alter the ability to mount an appropriate response to an acute inflammatory or adaptive immune challenge using a preclinical model. Short-term treatment of healthy mice with a dose of RIS that achieves plasma concentrations within the low clinical range resulted in disrupted response to an inflammatory (LPS) challenge compared to vehicle controls. Furthermore, RIS also prevented treated animals from mounting an antibody response following vaccination with Pneumovax23®. These data indicate that short-to intermediate-term exposure to clinically relevant levels of RIS dysregulate innate and adaptive immune responses, which may affect susceptibility to respiratory infections, including COVID-19.